BioAge Labs, Inc. (BIOA)
Automate Your Wheel Strategy on BIOA
With Tiblio's Option Bot, you can configure your own wheel strategy including BIOA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BIOA
- Rev/Share 0.0405
- Book/Share 8.7355
- PB 0.5357
- Debt/Equity 0.0296
- CurrentRatio 13.6833
- ROIC -0.2504
- MktCap 167778173.0
- FreeCF/Share -1.5064
- PFCF -3.1067
- PE -2.3616
- Debt/Assets 0.0269
- DivYield 0
- ROE -0.3774
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 5
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | BIOA | William Blair | -- | Market Perform | -- | -- | Feb. 28, 2025 |
| Downgrade | BIOA | Morgan Stanley | Overweight | Underweight | $40 | $5 | Dec. 10, 2024 |
| Downgrade | BIOA | Jefferies | Buy | Hold | $42 | $7 | Dec. 9, 2024 |
| Downgrade | BIOA | Citigroup | Buy | Neutral | $45 | $7 | Dec. 9, 2024 |
| Initiation | BIOA | Morgan Stanley | -- | Overweight | -- | $40 | Oct. 21, 2024 |
| Initiation | BIOA | Citigroup | -- | Buy | -- | $45 | Oct. 21, 2024 |
| Initiation | BIOA | Jefferies | -- | Buy | -- | $42 | Oct. 21, 2024 |
News
BIOAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Published: July 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against BioAge Labs, Inc. (NASDAQ: BIOA) on behalf of long-term stockholders following a class action complaint that was filed against BioAge on January 7, 2024 with a Class Period pursuant and/or traceable to BioAge's registration statement for the initial public offering held on or about September 26, 2024. Our investigation concerns whether the board of directors of BioAge have breached their fiduciary duties to the company.
Read More
BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank
Published: June 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company to generate and analyze molecular profiles from over 17,000 samples from the HUNT Biobank in Norway to accelerate discovery of drug targets for aging-related diseases New data deepen platform insights into the biology of resilience across multiple therapeutic indications EMERYVILLE, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced the launch of an initiative to comprehensively profile and analyze samples from the HUNT Biobank in Norway.
Read More
BIOAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against BioAge Labs, Inc. (NASDAQ: BIOA) on behalf of long-term stockholders following a class action complaint that was filed against BioAge on January 7, 2024 with a Class Period pursuant and/or traceable to BioAge's registration statement for the initial public offering held on or about September 26, 2024. Our investigation concerns whether the board of directors of BioAge have breached their fiduciary duties to the company.
Read More
BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
RICHMOND, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging, today provided business updates and reported its first quarter 2025 financial results.
Read More
Investors Who Lost Money on BioAge Labs, Inc. (BIOA) Should Contact Levi & Korsinsky About Pending Class Action - BIOA
Published: March 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bioage-labs-inc-lawsuit-submission-form?prid=135031&wire=1 or contact Joseph E. Levi, Esq.
Read More
Lost Money on BioAge Labs, Inc. (BIOA)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
Published: March 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in BioAge Labs, Inc. ("BioAge" or the "Company") (NASDAQ: BIOA) of a class action securities lawsuit.
Read More
Shareholders that Lost Money on BioAge Labs, Inc. (BIOA) Should Contact Levi & Korsinsky About Pending Class Action - BIOA
Published: March 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bioage-labs-inc-lawsuit-submission-form?prid=135011&wire=1 or contact Joseph E. Levi, Esq.
Read More
BIOA LAWSUIT ALERT: Levi & Korsinsky Notifies BioAge Labs, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Published: March 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bioage-labs-inc-lawsuit-submission-form?prid=134966&wire=1 or contact Joseph E. Levi, Esq.
Read More
About BioAge Labs, Inc. (BIOA)
- IPO Date 2024-09-26
- Website https://bioagelabs.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Kristen Fortney
- Employees 62